Radiation Oncology

Radiation oncology is a medical specialty that uses radiation therapy to treat cancer. The radiation therapy channel covers all aspects of radiation oncology technology. Radiation therapy includes linear accelerators (LINAC), proton therapybrachytherapyimage guided radiation therapy (IGRT)focused ultrasoundstereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), treatment planning systems and tomotherapy.

Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging

Getty Images

News | PET Imaging | January 18, 2021
January 18, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and...
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the COVID-19 pandemic on cancer diagnoses,...
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021
January 13, 2021 — The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast...
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
January 11, 2021 — A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic...
Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound.

Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound. Image courtesy of UVA Health

News | Focused Ultrasound Therapy | January 08, 2021
January 8, 2021 — A scalpel-free alternative to brain surgery has the potential to benefit people with Parkinson’s...
Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement solutions, announced that it has acquired Sun Nuclear Corporation. Sun Nuclear is the global leader in radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world.
News | Quality Assurance (QA) | January 08, 2021
January 8, 2021 — Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement...
RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

Image courtesy of Siemens Healthineers

News | Linear Accelerators | January 04, 2021
January 4, 2021 — RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular...
RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.
News | Brachytherapy Systems | December 29, 2020
December 29, 2020 — RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning...
C-RAD has been selected as the partner to implement surface tracking technology for three proton cancer treatment centers in the U.S.
News | Proton Therapy | December 28, 2020
December 28, 2020 — C-RAD offers a specific version of its Catalyst System for use in proton and particle therapy -...
A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.

A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.

News | Nuclear Imaging | December 22, 2020
December 22, 2020 — Researchers in the DOE Isotope Program have developed an effective radionuclide, cerium-134, as a...
According to recent studies, an increase in the COVID-19 positivity rate correlates to an increase in mortality from non-coronavirus-related diseases. This includes breast cancer, and researchers believe fear of contracting the virus compels patients to stay home instead of completing their post-lumpectomy radiotherapy regimens.

Image courtesy of Zeiss

News | Radiation Therapy | December 21, 2020
December 21, 2020 — According to recent studies, an increase in the COVID-19 positivity rate correlates to an increase...
Companies to develop compatibility of Philips’ MR Ingenia 3.0T and 1.5T systems with the InSightec Exablate Neuro platform
News | Focused Ultrasound Therapy | December 18, 2020
December 18, 2020 — Philips and InSightec, a global healthcare company focused on the therapeutic power of acoustic...
 Fujifilm Medical Systems U.S.A., Inc. announced today that UroPartners, the largest urology practice in Illinois and top five in the nation, has chosen to standardize on the Persona CT computed tomography (CT) system to accelerate their oncology treatment planning capabilities
News | Computed Tomography (CT) | December 17, 2020
December 17, 2020 — Fujifilm Medical Systems U.S.A., Inc. announced that UroPartners, the largest urology practice in ...
Primary liver cancer is on the rise worldwide, largely due to an increase in hepatitis C infections and chronic liver disease

Getty Images

News | Radiation Therapy | December 16, 2020
December 16, 2020 — Primary liver cancer is on the rise worldwide, largely due to an increase in hepatitis C infections...
Older patients with hormone receptor-positive breast cancer who did not receive radiation therapy after breast-conserving surgery had higher rates of local recurrence but similar 10-year survival rates when compared to patients who received postoperative radiation therapy, according to updated 10-year data from the PRIME II study, presented at the 2020 San Antonio Breast Cancer Symposium

Getty Images

News | Radiation Therapy | December 15, 2020
December 15, 2020 — Older patients with hormone receptor-positive breast cancer who did not receive radiation therapy...
The first MRI-guided radiation therapy system provides real-time view of tumors during radiation treatment
News | Radiation Therapy | December 15, 2020
December 15, 2020 — Hoag Memorial Hospital Presbyterian became the only hospital in Orange County, and one of the first...
CXCR4-directed PET correlates with MRI-determined lymphoma lesions. Depicted are representative MR images (T1c- and FLAIR- sequences), and the corresponding CXCR4- directed PET images and fusion images (MRI-FLAIR and PET), of two patients with PCNSL and SCNSL, respectively. Images created by Department of Nuclear Medicine, School of Medicine, Technische Universität München, Munich, Germany.

CXCR4-directed PET correlates with MRI-determined lymphoma lesions. Depicted are representative MR images (T1c- and FLAIR- sequences), and the corresponding CXCR4- directed PET images and fusion images (MRI-FLAIR and PET), of two patients with PCNSL and SCNSL, respectively. Images created by Department of Nuclear Medicine, School of Medicine, Technische Universität München, Munich, Germany.

News | PET Imaging | December 14, 2020
December 14, 2020 — Positron emission tomography (PET) imaging with 68Ga-pentixafor is an effective diagnostic tool for...
Among patients with breast cancer treated with radiotherapy, under-recognition of symptoms was common in reports of pain, pruritus, edema and fatigue, with younger patients and Black patients having significantly increased odds of symptom under-recognition, according to data presented at the 2020 San Antonio Breast Cancer Symposium

Getty Images

News | Women's Health | December 14, 2020
December 14, 2020 — Among patients with breast cancer treated with radiotherapy, under-recognition of symptoms was...
A new study finds that significant symptoms in young and Black patients are more likely to be under-recognized

Getty Images

News | Radiation Therapy | December 10, 2020
December 10, 2020 — Physicians did not recognize side effects from radiation therapy in more than half of breast cancer...
Post-neoadjuvant therapy changes in metabolic metrics from PET/MRI and morphologic metrics from CT were associated with pathologic response and overall survival in patients with pancreatic ductal adenocarcinoma

Pre-treatment (A-C) and post-treatment (D-F) images after eight cycles of systemic FOLFIRINOX and consolidative chemoradiation. Baseline CA 19-9 was 145 U/ml. Pre-treatment whole body axial fused PET/MRI showed FDG avid lesion in body of pancreas (arrow, A) with SUVmax 7.1 and SUVgluc 8.0. Lesion was hypo-enhancing on axial contrast-enhanced T1-weighted (T1W) MR image (arrow, B) from focused abdominal PET/MRI and on CT (arrow, C). Pre-treatment CT tumor volume was 10.3 cm3. Post-treatment whole body axial fused PET/MRI showed complete metabolic response (arrow D) with SUVmax 1.9 and SUVgluc 1.9. Lesion was indistinct on axial contrast-enhanced T1W MRI (arrow, E) and CT (arrow, F), and there was upstream pancreatic parenchymal atrophy. Post-treatment CT tumor volume was 0.46 cm3. There was normalization of CA 19-9. Relative change in SUVmax (ΔSUVgluc) was -73%, and relative change in SUVgluc (ΔSUVgluc) was -76%. Based on change in tumor size, response was categorized as partial response per RECIST. Relative change in tumor volume (ΔTvol) was -96%. Pathology showed major pathologic response (College of American Pathologists score 1.) Images courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | PET-MRI | December 10, 2020
December 10, 2020 — According to an open-access Editor's Choice article in ARRS' American Journal of Roentgenology (AJR...